Claritev (CTEV) Aandelenoverzicht
Claritev Corporation biedt, samen met haar dochterondernemingen, oplossingen voor data-analyse en technologie voor end-to-end kostenbeheer, betaling en integriteit van inkomsten aan de gezondheidszorg in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
+ 1 meer risico
CTEV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Claritev Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$35.98 |
| 52 Week Hoogtepunt | US$73.68 |
| 52 Week Laag | US$11.50 |
| Bèta | 0.89 |
| 1 maand verandering | -5.61% |
| 3 maanden verandering | 17.54% |
| 1 Jaar Verandering | -41.48% |
| 3 jaar verandering | -47.09% |
| 5 jaar verandering | -85.88% |
| Verandering sinds IPO | -90.75% |
Recent nieuws en updates
Narratiefupdate • Sep 10
CTEV: DOJ Antitrust Expansion Will Test Elevated FY26 Execution Expectations
Claritev's updated analyst narrative reflects a higher internal fair value estimate of $30, supported by recent Street price target increases into the $37 to $45 range as analysts factor in the Q2 beat, the raised FY26 outlook, and improving bookings momentum, while still flagging high leverage and a slow deleveraging path as key risks. Analyst Commentary Recent Street research on Claritev clusters around higher price targets and supportive views on the Q2 print, but there are still clear points of caution that matter for anyone weighing the stock’s risk and reward trade off.
Narratiefupdate • Aug 27
CTEV: Q2 Beat And Raised FY26 Outlook Will Support Future Expansion
Analysts have raised Claritev's fair value estimate from $61.00 to about $72.10, citing higher modeled revenue growth, slightly stronger profit margins, and updated P/E assumptions following recent price target increases at several firms after Q2 results and refreshed outlooks. Analyst Commentary Recent research updates on Claritev show a cluster of higher price targets and generally constructive commentary, especially around the latest Q2 results, bookings trends, and medium term outlook.Recent updates
Narratiefupdate • Sep 10
CTEV: DOJ Antitrust Expansion Will Test Elevated FY26 Execution Expectations
Claritev's updated analyst narrative reflects a higher internal fair value estimate of $30, supported by recent Street price target increases into the $37 to $45 range as analysts factor in the Q2 beat, the raised FY26 outlook, and improving bookings momentum, while still flagging high leverage and a slow deleveraging path as key risks. Analyst Commentary Recent Street research on Claritev clusters around higher price targets and supportive views on the Q2 print, but there are still clear points of caution that matter for anyone weighing the stock’s risk and reward trade off.Narratiefupdate • Aug 27
CTEV: Q2 Beat And Raised FY26 Outlook Will Support Future Expansion
Analysts have raised Claritev's fair value estimate from $61.00 to about $72.10, citing higher modeled revenue growth, slightly stronger profit margins, and updated P/E assumptions following recent price target increases at several firms after Q2 results and refreshed outlooks. Analyst Commentary Recent research updates on Claritev show a cluster of higher price targets and generally constructive commentary, especially around the latest Q2 results, bookings trends, and medium term outlook.
Narratiefupdate • Aug 12
CTEV: Q2 Beat And Growing Bookings Will Support Future Upside Potential
Claritev's updated analyst price target rises from about $36.83 to roughly $43.83 as analysts respond to recent Q2 beats, higher long term bookings expectations, and modestly adjusted assumptions for revenue growth, profit margin, discount rate, and future P/E multiples. Analyst Commentary Recent research on Claritev points to a mix of optimism around growth and execution, alongside clear concerns around balance sheet risk and the pace of improvement.Narratiefupdate • Jul 09
CTEV: Early FY26 Contract Wins Will Support Future Customer Expansion
Analysts have lowered the Claritev fair value estimate from $86 to $61, reflecting updated assumptions around profit margins and a higher future P/E. They also highlight ongoing efforts to grow contract wins, expand the customer base, and support a return to growth.Narratiefupdate • Jun 25
CTEV: New Contracts And Management Changes Will Support Future Upside Potential
Analysts have trimmed their average price target on Claritev to $61, reflecting a reset from prior expectations near $90. The revised target continues to be associated with support from new coverage initiations, recent management efforts, and recent contract wins cited across recent research.Narratiefupdate • Jun 11
CTEV: New Contracts And Management Changes Will Drive Future Upside Potential
Claritev's updated analyst price target has moved lower by about $3 to $36.83, as analysts factor in slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple. This is partly offset by higher projected profit margins and recent Street targets that range from $32 to $61.Narratiefupdate • May 27
CTEV: Early FY26 Contracts And DOJ Probe Will Shape Execution Outlook
Analysts have lifted their Claritev price target to $40 from $21, pointing to stronger early FY26 contract wins and new customer additions as key drivers behind the updated fair value estimate of $22 and a higher future P/E assumption. Analyst Commentary Recent research points to improving sentiment around Claritev, with analysts highlighting early FY26 contract wins of US$44m in annual contract value and six new customer additions as key supports for the higher fair value estimate and revised P/E assumption behind the US$40 price target.Narratiefupdate • May 05
CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside
Claritev's analyst fair value has been revised from $42.75 to $39.80 as analysts factor in slightly lower profit margin assumptions and a small reset in future P/E expectations, in line with recent price target trims from several firms following updated guidance and investment plans. Analyst Commentary Street research on Claritev has shifted toward more conservative assumptions on margin, revenue mix and investment timing, while still highlighting areas where execution could support the current valuation over time.Seeking Alpha • Apr 20
Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)
Summary Claritev is upgraded to 'Hold' after a 32% decline, with the short thesis largely played out. Legacy business revenues are stabilizing, showing 6.2% YoY Q4 growth and accelerating full-year growth, despite margin pressure from regulatory changes. BenInsights' failed pivot is now fully reflected in CTEV’s valuation; any positive developments could act as catalysts. CTEV’s $4.6B debt load and negligible free cash flow keep valuation unattractive, with a 9.2x EV/EBITDA multiple deemed expensive for its risk profile. Read the full article on Seeking AlphaNarratiefupdate • Apr 20
CTEV: Entrenched Payer Role And 2026 Buyback Capacity Will Support Upside
Claritev's analyst price target has been reset lower, with the model's fair value estimate moving from $44.75 to $42.75 as analysts factor in reduced formal targets from Citi, Guggenheim, and Wells Fargo, along with updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Claritev has coalesced around lower price targets, but the tone is mixed, with analysts highlighting both upside drivers and areas where execution and guidance keep them cautious.Narratiefupdate • Apr 05
CTEV: Entrenched Position And Buybacks Will Support Volume Driven Earnings Power
Analysts cut the Claritev price target to $21, with updated models reflecting slightly different revenue growth, profit margin, and future P/E assumptions following recent guidance and sector research. Analyst Commentary Recent Street research on Claritev points to a reset in expectations, with several bearish analysts cutting price targets and highlighting execution and balance sheet risks, even as ratings in the sample remain unchanged.Narratiefupdate • Mar 22
CTEV: Entrenched Position And Buybacks Will Support More Sustainable Future Margins
Analysts have reduced the Claritev price target to $21 from $33, reflecting updated expectations for slower revenue growth, slightly lower profit margins, and a lower future P/E multiple, even as they cite solid recent results and continued investment in growth initiatives. Analyst Commentary Recent research updates show a clear reset in expectations for Claritev, with multiple firms cutting price targets while generally maintaining existing ratings.Narratiefupdate • Mar 07
CTEV: Entrenched Payer Role And 2026 Guidance Reset Will Support Upside
The analyst price target for Claritev has been reduced from $57.25 to $44.75. Analysts cited lower revenue growth and profit margin assumptions, as well as a revised future P/E expectation following recent price target cuts from multiple firms.Narratiefupdate • Feb 21
CTEV: Entrenched Position And Deleveraging Will Support More Sustainable Future Margins
Claritev's analyst price target has been reset lower to $63, down from $80, as analysts factor in a slightly lower future P/E assumption of 9.87x. They also note that the company remains an entrenched vendor with accelerating revenue but elevated leverage that can weigh on valuation.Narratiefupdate • Feb 06
CTEV: Entrenched Payer Position And Deleveraging Will Support Future Upside
Analysts have trimmed their fair value estimate for Claritev to $57.25 from $85, citing updated Street price targets in the $33 to $63 range and reduced future P/E assumptions, while also acknowledging steady revenue growth and margin expectations. Analyst Commentary Bullish and cautious views on Claritev are both in play, and that split is driving a wide range of price targets and valuation opinions.Narratiefupdate • Jan 23
CTEV: Revenue Recovery And Deleveraging Will Support More Sustainable Future Margins
Narrative Update Opening Analysts have trimmed their fair value estimate for Claritev from $80 to $33, citing a lower Street price target that ranges from $63 at the high end to $33, and a view that stronger revenue growth and steady margins are now balanced by a less premium future P/E and concerns about elevated leverage. Analyst Commentary Recent research updates on Claritev highlight a split view, with some firms still constructive on the long term while taking down price targets and others starting coverage at more neutral levels.Analyse-artikel • Jan 18
Claritev Corporation (NYSE:CTEV) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...Narratiefupdate • Jan 09
CTEV: Best In Class Margins And Deleveraging Efforts Will Support Upside
Analysts have raised their average price target on Claritev to US$74 from US$55, citing confidence in the company's ability to accelerate growth while maintaining strong margins, even as some remain cautious about leverage and valuation. Analyst Commentary Recent research paints a mixed picture around Claritev, with bullish analysts highlighting growth potential and margin strength, while more cautious voices focus on balance sheet risk and how much optimism is already reflected in the share price.Narratiefupdate • Dec 25
CTEV: Mid Single Digit Revenue Recovery Will Support Best In Class Margins
Analysts have raised their price target on Claritev from 55 dollars to 80 dollars, citing increased confidence that the company can reaccelerate to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Recent research notes highlight a more constructive stance on Claritev's long term prospects, with the latest upgrade reflecting greater confidence in management's roadmap to restore sustainable growth while preserving strong profitability.Narratiefupdate • Dec 11
CTEV: Best-In-Class Margins Will Support Return To Mid-Single-Digit Expansion
Claritev's analyst price target has been raised to $74 from $55, as analysts cite growing confidence that the company can return to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Bullish Takeaways Bullish analysts view the higher $74 target as reflecting renewed confidence in Claritev's ability to reaccelerate revenue growth while preserving margin discipline.Narratiefupdate • Nov 27
CTEV: Upgraded Buy Rating Will Drive Growth Momentum and Margin Strength
Analysts have raised Claritev’s price target from $80 to $85, reflecting renewed confidence in the company’s accelerating growth and its ability to maintain strong margins. Analyst Commentary Analyst sentiment around Claritev continues to evolve as the company demonstrates a strong execution track record and new growth initiatives.Narratiefupdate • Nov 06
CTEV: Upgraded Buy Rating Will Drive Renewed Momentum Through 2026
Narrative Update on Claritev Analysts have raised Claritev's price target from $55 to $74, citing increased confidence in the company's plan to accelerate growth and maintain industry-leading margins. Analyst Commentary Following the recent upgrade and price target revision, analysts have shared a range of insights on Claritev’s prospects and execution trajectory.Analyse-artikel • Nov 01
Improved Revenues Required Before Claritev Corporation (NYSE:CTEV) Stock's 35% Jump Looks Justified
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 35% gain in the last month alone...Narratiefupdate • Oct 23
Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments
Analysts have raised Claritev's fair value estimate from $70.50 to $80.00. They cite growing confidence in the company's accelerated revenue growth outlook and sustained margins following the recent price target upgrade.Analyse-artikel • Sep 09
Claritev Corporation's (NYSE:CTEV) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Despite an already strong run, Claritev Corporation ( NYSE:CTEV ) shares have been powering on, with a gain of 27% in...Narratiefupdate • Aug 08
Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion
Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50. What's in the News Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.Analyse-artikel • Jul 30
Claritev (NYSE:CTEV) Use Of Debt Could Be Considered Risky
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Jul 09
Claritev Corporation's (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 25% gain in the last month alone...Nieuw narratief • May 30
AI And Global Partnerships Will Reshape Personalized Medicine
AI-powered analytics, digital transformation, and global expansions position Claritev to monetize higher-value healthcare solutions and tap into growing, aging populations.Analyse-artikel • May 15
Claritev Corporation (NYSE:CTEV) Shares Fly 30% But Investors Aren't Buying For Growth
Claritev Corporation ( NYSE:CTEV ) shareholders would be excited to see that the share price has had a great month...Analyse-artikel • Mar 20
Little Excitement Around Claritev Corporation's (NYSE:CTEV) Revenues As Shares Take 28% Pounding
Claritev Corporation ( NYSE:CTEV ) shares have retraced a considerable 28% in the last month, reversing a fair amount...Analyse-artikel • Feb 03
There's No Escaping MultiPlan Corporation's (NYSE:MPLN) Muted Revenues Despite A 29% Share Price Rise
MultiPlan Corporation ( NYSE:MPLN ) shares have continued their recent momentum with a 29% gain in the last month...Analyse-artikel • Dec 20
MultiPlan Corporation (NYSE:MPLN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Those holding MultiPlan Corporation ( NYSE:MPLN ) shares would be relieved that the share price has rebounded 28% in...Analyse-artikel • Dec 13
Here's Why MultiPlan (NYSE:MPLN) Is Weighed Down By Its Debt Load
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Oct 20
MultiPlan Corporation (NYSE:MPLN) Shares Fly 55% But Investors Aren't Buying For Growth
MultiPlan Corporation ( NYSE:MPLN ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Rendement voor aandeelhouders
| CTEV | US Healthcare Services | US Markt | |
|---|---|---|---|
| 7D | -6.4% | -4.1% | -0.9% |
| 1Y | -41.5% | -18.2% | 14.2% |
Rendement versus industrie: CTEV presteerde slechter dan de US Healthcare Services -sector, die het afgelopen jaar een rendement van -18.2 % opleverde.
Rendement versus markt: CTEV presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 14.2 % opleverde.
Prijsvolatiliteit
| CTEV volatility | |
|---|---|
| CTEV Average Weekly Movement | 13.0% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: De aandelenkoers van CTEV is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van CTEV is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1980 | 3,000 | Travis Dalton | www.claritev.com |
Claritev Corporation biedt, samen met haar dochterondernemingen, end-to-end oplossingen op het gebied van gegevensanalyse en technologie voor kostenbeheer, betaling en integriteit van inkomsten aan de gezondheidszorgsector in de Verenigde Staten. Het bedrijf biedt oplossingen voor informatie over claims, waaronder op referentieprijzen gebaseerde prijzen, onderhandelingsdiensten, diensten voor onaangekondigde facturen en Vistara; netwerkoplossingen, zoals primaire netwerken, aanvullende netwerken en diensten voor netwerkopbouw en netwerkbeheer; en oplossingen voor integriteit van betaling en inkomsten, waaronder klinische onderhandeling, integriteit vóór betaling, integriteit na betaling en diensten voor integriteit van inkomsten. Het biedt ook data- en analyseoplossingen bestaande uit PlanOptix, CompleteVue, BenInsights, risicoscores en aanvullende carrierdiensten.
Claritev Corporation Samenvatting
| CTEV fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$609.77m |
| Inkomsten(TTM) | -US$283.11m |
| Inkomsten(TTM) | US$994.67m |
0.6x
P/S-verhouding-2.2x
Koers/WinstverhoudingIs CTEV overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CTEV resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$994.67m |
| Kosten van inkomsten | US$268.90m |
| Brutowinst | US$725.77m |
| Overige uitgaven | US$1.01b |
| Inkomsten | -US$283.11m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -16.71 |
| Brutomarge | 72.97% |
| Nettowinstmarge | -28.46% |
| Schuld/Eigen Vermogen Verhouding | -1,624.0% |
Hoe presteerde CTEV op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/13 22:06 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Claritev Corporation wordt gevolgd door 9 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Steven Valiquette | Barclays |
| Glen Santangelo | Barclays |
| Andrew D'Silva | B. Riley Securities, Inc. |